Clinical Trial Detail

NCT ID NCT02318368
Title A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors AVEO Pharmaceuticals, Inc, Biodesix
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

Erlotinib + Ficlatuzumab

Age Groups: adult

No variant requirements are available.